Katherine P. Mueller

Katherine P. Mueller

Auto-generated profile, based on publicly available information

Katherine P. Mueller

Department of Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 April 2024 in Nature
Verified
Journal Article
Open access
PDF file
ADAlexander E. Doan
Alexander E. Doan
KMKatherine P. Mueller
Katherine P. Mueller
ACAndy Y. Chen
Andy Y. Chen
GRGeoffrey T. Rouin
Geoffrey T. Rouin
YCYingshi Chen
Yingshi Chen
EWEvan W. Weber
Evan W. Weber
A major limitation of chimeric antigen receptor (CAR) T cell therapies is the poor persistence of these cells in vivo1. The expression of memory-associated genes in CAR T cells is linked to their long-term persistence in patients and clinical efficacy2–6, suggesting that memory programs may underpin durable CAR T cell function. Here we show that the transcription factor FOXO1 is responsible for promoting memory and restraining exhaustion in human CAR T cells. Pharmacological inhibition or gene editing of endogenous FOXO1 diminished the expression of memory-associated genes, promoted an exhaustion-like phenotype and impaired the antitumour activity of CAR T cells. Overexpression of FOXO1 induced a gene-expression program consistent with T cell memory and increased chromatin accessibility at FOXO1-binding motifs. CAR T cells that overexpressed FOXO1 retained their function, memory potential and metabolic fitness in settings of chronic stimulation, and exhibited enhanced persistence and tumour control in vivo. By contrast, overexpression of TCF1 (encoded by TCF7) did not enforce canonical memory programs or enhance the potency of CAR T cells. Notably, FOXO1 activity correlated with positive clinical outcomes of patients treated with CAR T cells or tumour-infiltrating lymphocytes, underscoring the clinical relevance of FOXO1 in cancer immunotherapy. Our results show that overexpressing FOXO1 can increase the antitumour activity of human CAR T cells, and highlight memory reprogramming as a broadly applicable approach for optimizing therapeutic T cell states.

27 July 2020 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
AWAlex J. Walsh
Alex J. Walsh
KMKatherine P. Mueller
Katherine P. Mueller
KTKelsey Tweed
Kelsey Tweed
IJIsabel Jones
Isabel Jones
CWChristine M. Walsh
Christine M. Walsh
MSMelissa Skala
Melissa Skala

14 January 2021 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
WLWoojong Lee
Woojong Lee
BKBrock Kingstad-Bakke
Brock Kingstad-Bakke
BPBrett Paulson
Brett Paulson
ALAutumn Larsen
Autumn Larsen
KOKatherine Overmyer
Katherine Overmyer
MSMarulasiddappa Suresh
Marulasiddappa Suresh
There is a critical need for adjuvants that can safely elicit potent and durable T cell-based immunity to intracellular pathogens. Here, we report that parenteral vaccination with a carbomer-based adjuvant, Adjuplex (ADJ), stimulated robust CD8 T-cell responses to subunit antigens and afforded effective immunity against respiratory challenge with a virus and a systemic intracellular bacterial infection. Studies to understand the metabolic and molecular basis for ADJ’s effect on antigen cross-presentation by dendritic cells (DCs) revealed several unique and distinctive mechanisms. ADJ-stimulated DCs produced IL-1β and IL-18, suggestive of inflammasome activation, butin vivoactivation of CD8 T cells was unaffected in caspase 1-deficient mice. Cross-presentation induced by TLR agonists requires a critical switch to anabolic metabolism, but ADJ enhanced cross presentation without this metabolic switch in DCs. Instead, ADJ induced in DCs, an unique metabolic state, typified by dampened oxidative phosphorylation and basal levels of glycolysis. In the absence of increased glycolytic flux, ADJ modulated multiple steps in the cytosolic pathway of cross-presentation by enabling accumulation of degraded antigen, reducing endosomal acidity and promoting antigen localization to early endosomes. Further, by increasing ROS production and lipid peroxidation, ADJ promoted antigen escape from endosomes to the cytosol for degradation by proteasomes into peptides for MHC I loading by TAP-dependent pathways. Furthermore, we found that induction of lipid bodies (LBs) and alterations in LB composition mediated by ADJ were also critical for DC cross-presentation. Collectively, our model challenges the prevailing metabolic paradigm by suggesting that DCs can perform effective DC cross-presentation, independent of glycolysis to induce robust T cell-dependent protective immunity to intracellular pathogens. These findings have strong implications in the rational development of safe and effective immune adjuvants to potentiate robust T-cell based immunity.

23 April 2024 in Nature
Verified
Journal Article
Open access
PDF file
ADAlexander E. Doan
Alexander E. Doan
KMKatherine P. Mueller
Katherine P. Mueller
ACAndy Y. Chen
Andy Y. Chen
GRGeoffrey T. Rouin
Geoffrey T. Rouin
YCYingshi Chen
Yingshi Chen
EWEvan W. Weber
Evan W. Weber

8 August 2021 in bioRxiv
Verified
Preprint
Open access
PDF file
KMKatherine P. Mueller
Katherine P. Mueller
NPNicole J. Piscopo
Nicole J. Piscopo
MFMatthew H. Forsberg
Matthew H. Forsberg
LSLouise A. Saraspe
Louise A. Saraspe
ADAmritava Das
Amritava Das
KSKrishanu Saha
Krishanu Saha
Background: Chimeric antigen receptor (CAR) T cells traditionally harbor viral vector-based sequences that encode the CAR transgene in the genome. These T cell products have yet to show consistent anti-tumor activity in patients with solid tumors. Further, viral vector manufacturing is resource intensive, suffers from batch-to-batch variability, and includes several animal components, adding regulatory and supply chain pressures. Methods: Anti-GD2 CAR T cells were generated using CRISPR/Cas9 within nine days using recombinant Cas9 protein and nucleic acids, without any viral vectors or animal components. The CAR was specifically targeted to the T Cell Receptor Alpha Constant gene ( TRAC ). T cell products were characterized at the level of the genome, transcriptome, proteome, and secretome using CHANGE-seq, scRNA-seq, spectral cytometry, and ELISA assays. Functionality was evaluated in vivo in an NSG xenograft neuroblastoma model. Results: In comparison to traditional retroviral CAR T cells, virus-free CRISPR CAR (VFC-CAR) T cells exhibit TRAC -targeted genomic integration of the CAR transgene, elevation of transcriptional and protein characteristics associated with a memory phenotype, and low tonic signaling prior to infusion arising in part from the the knockout of the TCR. Upon exposure to the GD2 target antigen, anti-GD2 VFC-CAR T cells exhibited specific cytotoxicity against GD2+ cells in vitro and induced solid tumor regression in vivo , with robust homing, persistence, and low exhaustion against a human neuroblastoma xenograft model. Conclusions: This proof-of-principle study leveraging virus-free genome editing technology could enable flexible manufacturing of clinically relevant, high-quality CAR T cells to treat cancers, including solid tumors.

9 June 2022 in Swedish Aerospace Conference, FT2025
Verified
Conference Paper
Open access
PDF file
RHRian Hagebeuk
Rian Hagebeuk
KMKatherine Mueller
Katherine Mueller
The first page of an encrypted manuscript in the British Library bears the title, “The Subtelty [sic] of Witches,” and the year 1657, by author Ben Ezra Aseph. With a decryption key, it became clear that the manuscript is in fact a copy of verbs from a Latin dictionary, most likely an edition of Calepino. The title, year, and author have no apparent relation to the actual text, and were added later by an unknown person who likely had no knowledge of what the manuscript contained. After determining the range of dates the paper the manuscript was written on was found, and narrowing down the edition of the Calepino most likely copied from, we can now put the earliest possible date for the writing of the manuscript to 1543.